After SEBI clarification\, brokers wary of tighter margin norms

Market

After SEBI clarification, brokers wary of tighter margin norms

PALAK SHA Mumbai | Updated on September 15, 2020 Published on September 15, 2020

Margin collection in the equity cash segment will get stringent from Wednesday, brokers told BusinessLine. This is due to a clarification issued by the Securities and Exchange Board of India on Tuesday that mandates brokers to collect ‘additional’ margin from clients over and above the near 20 per cent compulsory margin. Till a fortnight ago, brokers had informed their clients that the 20 per cent upfront margin in the cash segment was mandatory from September 1. But now, ‘advance’ margin for buying stocks means that collection could go up to 50 per cent, brokers said.

Before September, the clearing corporations of exchanges did not impose any penalty on margin shortfall on brokers. Hence, they did not largely bother to collect any advance from clients for allowing them to trade or buy and sell stocks in the cash segment. From this month, SEBI asked brokers to collect value at risk (VAR) and extreme loss margin (ELM) from clients and announced penalty on short reporting. On an average, VAR and ELM on most stocks comes to around 20 per cent. Additional margin differs from scrip to scrip and could be as high as 50 per cent, depending on market volatility.

Margin collection

“Clients must ensure VAR and ELM are paid in advance and ‘other margins’ are paid as soon as calls are made. T+2 days has been allowed to collect margin from clients... it should not be construed that clients are allowed two days to pay margin due from them,” SEBI said.

According to brokers, when SEBI issued a circular on cash margin on July 31, there was no mention of ‘additional margin.’ Subsequently, exchanges issued circulars in August and talked about ‘additional margin.’ On Tuesday, SEBI clarification confirmed the point of ‘additional margin.’ Brokers say, since other margins differ from scrip to scrip they will have to configure their back-end and front-end software to update that daily and then link it with client payments, which is tedious.

As per SEBI’s clarification, ‘additional’ margin can be collected at pay-in, which follows the T+2 cycle. Brokers say, allowing additional margin collection during pay-in is just a ‘sham.’ For instance, if someone buys stocks worth ₹100 on Monday by paying ₹20 in advance, then as per SEBI’s clarification, if the additional margin is ₹30, the same can be collected on Wednesday. But if the additional margin is not collected on Wednesday, brokers will be penalised for a three-day margin shortfall.

Brokers say, no one would take the chance of ‘anticipating’ that a client will pay the margin at pay-in or even the next day of trade. If no payment is received from the client on Tuesday for stocks bought on Monday, and even if brokers sell the shares, there is still a risk of penalty.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on September 15, 2020
SEB
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.

After SEBI clarification\, brokers wary of tighter margin norms

Covid-19 reinfection ‘very rare' occurrence, not a matter of concern: ICMR DG | India News - Times of India

Covid-19 reinfection ‘very rare' occurrence, not a matter of concern: ICMR DG

Representative image
NEW DELHI: Coronavirus reinfection is possible even though it is a "very rare" occurrence, ICMR DG Balram Bhargava said on Tuesday and stressed that it is not a matter of serious concern.
The remarks come amid suspected cases of Covid-19 reinfection being reported from abroad and from Indian states like Telangana, Karnataka, Gujarat, Punjab and Maharashtra.
Responding to a question on the issue, Bhargava told a press conference that reinfection was "very, very rare" with Covid-19, but it can happen as had been seen in a case in Hong Kong.
"We have seen that someone gets measles and he is supposed to be protected all his life because he generates certain antibodies, but then we have seen reinfection occurring in measles.
"Similarly, we can have reinfection with Covid-19 as has been described by the case in Hong Kong and it is not a matter of serious concern,” Bhargava said.
In an earlier press conference, he had said that there was a need to find out how long the immunity lasts against the infection.
On coronavirus vaccine development, the ICMR director general said three vaccines are at clinical trial stages in the country and two indigenously ones developed by Cadila and Bharat Biotech have completed phase-I trial.
The results are being analysed and they have completed recruitment for the second phase, he said.
Serum Institute of India has completed phase II-B3 trials of the Oxford COVID-19 vaccine candidate. There was a pause of seven days. They will start the phase-III trial with 1,500 patients at 14 locations in India after clearances, Bhargava said.
The Drugs Controller General of India (DCGI) had directed Serum Institute of India to suspend any new recruitment in the phase-II and III clinical trial of the Oxford COVID-19 vaccine candidate till further orders in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries.
Speaking about the vaccine developed in Russia, the ICMR DG said their first study of 76 patients has been published in the journal Lancet, which is “showing good effectiveness and immune-antibody generation”. He said Russia has not yet completed Phase-III trial.
Dialogues are going on between the High-Level Committee on Vaccines and the Russian diplomats about the mechanisms for conducting Phase-III trial in India, he said.
British-Swedish biopharmaceutical giant AstraZeneca and the University of Oxford had on Saturday said that clinical trials for their coronavirus vaccine have resumed in the United Kingdom after Medicines and Healthcare products Regulatory Agency (MHRA) confirmed that the trials were safe.
The human trials resumed days after a pause had been announced in the trials after an adverse reaction in one of the participants.
Addressing a query on the national sero-survey, Bhargava said the survey, which was done in April-May and is being repeated after three months, has been completed in 68 out of 70 districts. After analysis of the results by this month end, the two studies can be compared, he said.
The senior official added that the sero-survey also brings out infection fatality rate, which was found to be between 0.5-0.6 in the last national sero-survey, which was much below than in many other countries.

    Coronavirus outbreak

    Trending Topics

    LATEST VIDEOS

    More from TOI

    Navbharat Times

    Featured Today in Travel

    Get the app